menu
    • menu
    [{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Nephrology","graph2":"Phase I","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"6","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"6","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"6","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Fortress Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Fuji Yakuhin \/ Fortress Biotech"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Urica Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Urica Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Fuji Yakuhin \/ Urica Therapeutics"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Eisai"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"15","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"14-C FYU-981","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"FFI-1010","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Sanwa Kagaku Kenkyusho","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Topiroxostat","moa":"Xanthine dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"}]

    Find Clinical Drug Pipeline Developments & Deals by Fuji Yakuhin

    Menu

    Fuji Yakuhin

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved FDF

                            Sponsor : Urica Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Addi...

                            Details : Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabso...

                            Product Name : Urece

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved FDF

                            Sponsor : Urica Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved FDF

                            Recipient : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatmen...

                            Details : Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.

                            Product Name : Urece

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved FDF

                            Recipient : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved FDF

                            Sponsor : Fortress Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America...

                            Details : Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.

                            Product Name : Urece

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 10, 2021

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved FDF

                            Sponsor : Fortress Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eisai and FUJI YAKUHIN Conclude License Agreement

                            Details : Under this agreement, Eisai will proceed with the development of dotinurad in China.

                            Product Name : Urece

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 25, 2020

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 18, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Pharmacology of FYU-981 (Final Formulation)

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-drug Interaction Study of FYU-981 and Oxaprozin

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FFI-1010

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of FFI-1010 in Pediatric Kidney Disease

                            Details : FFI-1010 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 17, 2017

                            Lead Product(s) : FFI-1010

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)

                            Details : FYU-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatic Insufficiency.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 11, 2017

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Recipient : Mochida Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth